Limits...
Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus.

Sun L, Kwok E, Gopaluni B, Vahidi O - Open Biomed Eng J (2011)

Bottom Line: However, its effects on patients are derived usually from clinical experiments.The combination treatment of insulin infusion plus oral metformin is shown to be superior than the monotherapy with oral metformin only.These results are consistent with the clinical understanding of the use of metformin.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemical and Biological Engineering, University of British Columbia, 2360 East Mall Vancouver, BC, Canada, V6T 1Z3.

ABSTRACT
Metformin is an antihyperglycemic agent commonly used for the treatment of Type II diabetes mellitus. However, its effects on patients are derived usually from clinical experiments. In this study, a dynamic model of Type II diabetes mellitus with the treatment of metformin is proposed. The Type II diabetic model is a modification of an existing compartmental diabetic model. The dynamic simulation of the metformin effect for a Type II diabetic patient is based on the pharmacokinetic and pharmacodynamic relationship with a human body. The corresponding model parameters are estimated by optimization using clinical data from published reports. Then, the effect of metformin in both intravenous and oral administration on a Type II diabetes mellitus model are compared. The combination treatment of insulin infusion plus oral metformin is shown to be superior than the monotherapy with oral metformin only. These results are consistent with the clinical understanding of the use of metformin. For further work, the model can be analyzed for evaluating the treatment of diabetes mellitus with different pharmacological agents.

No MeSH data available.


Related in: MedlinePlus

The glucose-lowering effect of metformin (500 mg) in the corresponding organ following a) intravenous and b) oral administration.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3102322&req=5

Figure 3: The glucose-lowering effect of metformin (500 mg) in the corresponding organ following a) intravenous and b) oral administration.

Mentions: The relationship between the mass of metformin and the glucose-lowering effect is based on the PK-PD model as described in the earlier section (eqs. (10)-(12)), and the metabolic rate of the corresponding compartment is then modified. For both intravenous and oral administrations, the glucose-lowering effects are shown in Fig. (3).


Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus.

Sun L, Kwok E, Gopaluni B, Vahidi O - Open Biomed Eng J (2011)

The glucose-lowering effect of metformin (500 mg) in the corresponding organ following a) intravenous and b) oral administration.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3102322&req=5

Figure 3: The glucose-lowering effect of metformin (500 mg) in the corresponding organ following a) intravenous and b) oral administration.
Mentions: The relationship between the mass of metformin and the glucose-lowering effect is based on the PK-PD model as described in the earlier section (eqs. (10)-(12)), and the metabolic rate of the corresponding compartment is then modified. For both intravenous and oral administrations, the glucose-lowering effects are shown in Fig. (3).

Bottom Line: However, its effects on patients are derived usually from clinical experiments.The combination treatment of insulin infusion plus oral metformin is shown to be superior than the monotherapy with oral metformin only.These results are consistent with the clinical understanding of the use of metformin.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemical and Biological Engineering, University of British Columbia, 2360 East Mall Vancouver, BC, Canada, V6T 1Z3.

ABSTRACT
Metformin is an antihyperglycemic agent commonly used for the treatment of Type II diabetes mellitus. However, its effects on patients are derived usually from clinical experiments. In this study, a dynamic model of Type II diabetes mellitus with the treatment of metformin is proposed. The Type II diabetic model is a modification of an existing compartmental diabetic model. The dynamic simulation of the metformin effect for a Type II diabetic patient is based on the pharmacokinetic and pharmacodynamic relationship with a human body. The corresponding model parameters are estimated by optimization using clinical data from published reports. Then, the effect of metformin in both intravenous and oral administration on a Type II diabetes mellitus model are compared. The combination treatment of insulin infusion plus oral metformin is shown to be superior than the monotherapy with oral metformin only. These results are consistent with the clinical understanding of the use of metformin. For further work, the model can be analyzed for evaluating the treatment of diabetes mellitus with different pharmacological agents.

No MeSH data available.


Related in: MedlinePlus